

STARD 2015

Section & Topic	Item No	Item	Reported on Page Number/ Line Number	Reported on Section/ Paragraph
TITLE OR ABSTRACT				
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC)	Page 3/Line 7-11	Abstract/Paragraph 2 (Methods)
ABSTRACT				
	2	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)	Page 2/Line 1-22 Page 3/Line 1-4	Abstract/Paragraph 1-4
INTRODUCTION				
	3	Scientific and clinical background, including the intended use and clinical role of the index test	Page 5/Line 13-23	Introduction/Paragraph 3
	4	Study objectives and hypotheses	Page 5/Line 21-23	Introduction/Paragraph 3
METHODS				
Study design	5	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study)	Page 6/Line 10-17	Methods/Study design and patients/Paragraph 2
Participants	6	Eligibility criteria	Page 6/Line 4-5	Method/Study design and patients/Paragraph 1
	7	On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)	Page 6/Line 3-9	Method/Study design and patients/Paragraph 1
	8	Where and when potentially eligible participants were identified (setting, location and dates)	Page 6/Line 3-5	Method/Study design and patients/Paragraph 1

	9	Whether participants formed a consecutive, random or convenience series	Page 6/Line 3-5	Method/Study design and patients/Paragraph 1
Test methods	10a	Index test, in sufficient detail to allow replication	Page 6/Line 19-22 Page 7/Line 1-9	Method/Working Process of SLN-CEUS/Paragraph 1
	10b	Reference standard, in sufficient detail to allow replication	Page 8/Line 10-12	Method/Statistical analysis/Paragraph 2
	11	Rationale for choosing the reference standard (if alternatives exist)	No alternative reference standard exist, since the pathologic result is the well-acknowledged golden standard for diagnosis.	No alternative reference standard exist, since the pathologic result is the well-acknowledged golden standard for diagnosis.
	12a	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory	Page 7/Line 6-16	Method/Working Process of SLN-CEUS/Paragraph 1-2
	12b	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory	Not mentioned since the pathologic result is the well-acknowledged golden standard for diagnosis.	Not mentioned since the pathologic result is the well-acknowledged golden standard for diagnosis.
	13a	Whether clinical information and reference standard results were available to the performers/readers of the index test	Page 6/Line 19-20	Method/Working Process of SLN-CEUS/Paragraph 1
	13b	Whether clinical information and index test results were available to the assessors of the reference standard	Page 8/Line 2-3	Method/Surgical Management/Paragraph 1

Analysis	14	Methods for estimating or comparing measures of diagnostic accuracy	Page 8/Line 5-9	Method/Statistical Analysis/Paragraph 1
	15	How indeterminate index test or reference standard results were handled	Page 7/Line 10-16	Method/Working Process of SLN-CEUS /Paragraph 2-3
	16	How missing data on the index test and reference standard were handled	NA, since the missing data has been excluded.	NA, since the missing data has been excluded.
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory	No analyses of variability in diagnostic accuracy, since our study is an exploratory study instead of a pre-specified study	No analyses of variability in diagnostic accuracy, since our study is an exploratory study instead of a pre-specified study
	18	Intended sample size and how it was determined	NA, since our study is a retrospective study.	NA, since our study is a retrospective study.
RESULTS				
Participants	19	Flow of participants, using a diagram	Figure 1	Figure 1
	20	Baseline demographic and clinical characteristics of participants	Page 9/Line 20-22 Table 1&2	Result/Baseline characteristics/Paragraph 1
	21a	Distribution of severity of disease in those with the target condition	Table 1&2	Table 1&2
	21b	Distribution of alternative diagnoses in those without the target condition	NA, since the alternative diagnoses do not affect our results, including identification rate, diagnostic efficacy and FNR	NA, since the alternative diagnoses do not affect our results, including identification rate, diagnostic efficacy and FNR
	22	Time interval and any clinical interventions between index test and reference standard	Page 7/Line 18	Method/Surgical Management/Paragraph 1
Test results	23	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	Table 3-5	Table 3-5
	24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	Page 10/Line 1-7	Results/Diagnostic efficacy/Paragraph 1
	25	Any adverse events from performing the index test or the reference standard	Not mentioned in our retrospective study, since the index test had shown its safety in previous study.	Not mentioned in our retrospective study, since the index test had shown its safety in previous study.

			Furthermore, the reference standard (SLNB/ALND) is the standard treatment in our patients.	Furthermore, the reference standard (SLNB/ALND) is the standard treatment in our patients.
DISCUSSION				
	26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	Page 16/Line 1-4	Discussion/Limitations/Paragraph 1
	27	Implications for practice, including the intended use and clinical role of the index test	Page 11/Line 21-22 Page 12/Line 7-8 Page 13/Line 4-6 Page 13/Line 11-13,15-17 Page 14/Line 8-10, 15-17, 22 Page 15/Line 1 Page 15/Line 14-16, 18-22	Discussion/Diagnostic efficacy/Paragraph 1-3 Discussion/Proportion of undermined diagnoses/Paragraph 2 Discussion/Identification rate/Paragraph 2 Discussion/FNR of SLNB/Paragraph 2-3
OTHER INFORMATION				
	28	Registration number and name of registry	NA, since it is not necessary for retrospective study.	NA, since it is not necessary for retrospective study.
	29	Where the full study protocol can be accessed	NA, since it is not necessary for retrospective study.	NA, since it is not necessary for retrospective study.
	30	Sources of funding and other support; role of funders	Page 18/Line 1-3	Acknowledgement

AIM

STARD stands for “Standards for Reporting Diagnostic accuracy studies” . This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

Explanation

A **diagnostic accuracy study** evaluates the ability of one or more medical tests to correctly classify study participants as having a **target condition**. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test**. A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants with the target condition who have a positive index test), and its **specificity** (the proportion without the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or “2x2” table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003. More information can be found on <http://www.equator-network.org/reporting-guidelines/stard>.

Article information: <https://dx.doi.org/10.21037/qims-22-901>

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.